Dravet syndrome: Insights into seizure and speech progression from registry data

1:1
Analysis of registry data offers critical insights into the progression of seizures and speech development in patients with Dravet syndrome.

This study utilises patient registry data to track the natural history of Dravet syndrome, focusing on how seizure frequency and speech abilities evolve over time. The findings provide a baseline for evaluating the efficacy of future therapeutic interventions.

Acces this publication (pdf)
Epilepsy & Behaviour

Year of publication

2025

Source

Epilepsy & Behavior

Link to cite

Acces to Link >

Author

elporte M, Verbeeck J, Brambilla I, Zimmermann G, Molenberghs G, Nabbout R, et al.

You might also be interested in

European Parliament

European Parliament draft report urges a binding EU rare disease action framework

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.
European Parliament Photograph

New European Parliament study maps options for an EU rare disease action plan

European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.
Publicaciones (1)

EU rare disease action plan- European Added Value Assessment

This study investigates possible measures that could be taken at EU level to address these challenges. It finds significant European added value in harmonising coordination and access across the 27 Member States, mainly in terms of improved diagnostic tools and availability of medical treatment, better health outcomes, particularly lower infant mortality, and improved well-being of family members and caregivers.
Rare Disease Day 2026 visual representation

One year of ERDERA: the European alliance built to accelerate rare disease research reports first results

28 February, across Europe and beyond: one year into delivery, ERDERA is advancing towards shorten diagnostic journeys and improved therapies for people living with a rare disease.

ERDERA's

search form